Research Article
Open Access
Targeting plasma membrane phosphatidylserine content to inhibit oncogenic KRAS function
Walaa E Kattan, Wei Chen, Xiaoping Ma, Tien Hung Lan, Dharini van der Hoeven, Ransome van der Hoeven, View ORCID ProfileJohn F Hancock Correspondence email
Walaa E Kattan
1Department of Integrative Biology and Pharmacology, McGovern Medical School, University of Texas Health Science Center, Houston, TX, USA
3The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA
Wei Chen
1Department of Integrative Biology and Pharmacology, McGovern Medical School, University of Texas Health Science Center, Houston, TX, USA
Xiaoping Ma
1Department of Integrative Biology and Pharmacology, McGovern Medical School, University of Texas Health Science Center, Houston, TX, USA
Tien Hung Lan
1Department of Integrative Biology and Pharmacology, McGovern Medical School, University of Texas Health Science Center, Houston, TX, USA
Dharini van der Hoeven
2Department of Diagnostic and Biomedical Sciences, School of Dentistry, University of Texas Health Science Center, Houston, TX, USA
Ransome van der Hoeven
2Department of Diagnostic and Biomedical Sciences, School of Dentistry, University of Texas Health Science Center, Houston, TX, USA
John F Hancock
1Department of Integrative Biology and Pharmacology, McGovern Medical School, University of Texas Health Science Center, Houston, TX, USA
3The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA
Published 26 August 2019. DOI: 10.26508/lsa.201900431
Statistics from Altmetric.com
Article usage
Inhibiting KRAS through PtdSer transport
Walaa E Kattan, Wei Chen, Xiaoping Ma, Tien Hung Lan, Dharini van der Hoeven, Ransome van der Hoeven, John F Hancock
Life Science Alliance Aug 2019, 2 (5) e201900431; DOI: 10.26508/lsa.201900431
In this Issue
Volume 2, No. 5
October 2019
Advertisement
Jump to section
Subjects
Related Articles
- No related articles found.
Cited By...
- A new ferrocene derivative blocks K-Ras localization and function by oxidative modification at His95
- Components of the phosphatidylserine endoplasmic reticulum to plasma membrane transport mechanism as targets for KRAS inhibition in pancreatic cancer
- The KRAS and other prenylated polybasic domain membrane anchors recognize phosphatidylserine acyl chain structure
- Scaffold association factor B (SAFB) is required for expression of prenyltransferases and RAS membrane association